The US Food and Drug Administration (FDA) is considering dispensing mail-back envelopes with outpatient opioid analgesic prescriptions.
The FDA will be seeking public comment on changes that would require opioid analgesics prescribed in outpatient settings to be disposed of via prepaid mail-back envelopes provided by pharmacists, according to an FDA news release.1
The changes would modify the current Opioid Analgesic Risk Evaluation and Mitigation strategy and would provide “a convenient, additional disposal option for patients beyond those already available such as flushing, commercially available in-home disposal products, collection kiosks, and takeback events.”
It is not uncommon for patients to have unused opioid analgesics on hand after outpatient surgical procedures, creating an environment of opportunity for nonmedical opioid use. Providing a mail-back envelope with these prescriptions can, the FDA said, reduce the quantity of unused medication in patient homes. This effort, coupled with patient education about disposal options, may increase the rate of disposal of unused opioids.
“The FDA is committed to addressing the opioid crisis on all fronts, including exploring new approaches that have the potential to decrease unnecessary exposure to opioids and prevent new cases of addiction,” said Robert M. Califf, MD, FDA Commissioner, in the news release. “Prescribing opioids for durations and doses that do not properly match the clinical needs of the patient not only increases the changes for misuse, abuse, and overdose, but it also increases the likeilihood of unnecessary exposure to unused medications.”
“[T]he mail-back envelope requirement…would complement current disposal programs and provide meaningful and attainable steps to improve the safe use and disposal,” he added.
These changes support the Department of Health & Human Services Overdose Prevention Strategy,2 which focuses on primary prevention, harm reduction, evidence-based treatment, and recovery support.
Public comments are being solicited until June 21, 2022.3
This article was originally published by sister publication Drug Topics.
References
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.